Items where Author is "Mokarian, F."

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 9.

(2022) Diagnostic Value of Nonacid Nucleic Blood Tumor Marker Panels in Early Diagnosing Breast Cancer: A Systematic Review and Network Meta-Analysis. DISEASE MARKERS. ISSN 0278-0240 1875-8630 J9 - DIS MARKERS

(2021) Lack of association between c1236t, g2677t/a and c3435t variants of the abcb1 gene and imatinib response in iranian chronic myeloid leukemia patients. Journal of Sciences, Islamic Republic of Iran. pp. 121-130. ISSN 10161104 (ISSN)

(2016) Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer. Advanced biomedical research. p. 10. ISSN 2277-9175 (Print) 2277-9175 (Linking)

(2016) Genomic rearrangement screening of the BRCA1 from seventy Iranian high-risk breast cancer families. Journal of Research in Medical Sciences. ISSN 1735-1995

(2015) Coping Skill Improve Quality of Life in Women with Breast Cancer and Maladaptive Coping Style. Psycho-Oncology. pp. 212-213. ISSN 1057-9249

(2015) Expression of Ck-19 in Circulating Tumour Cells from Women with Metastatic Breast Cancer. European Journal of Cancer. E8-E8. ISSN 0959-8049

(2015) The Performance of the Nottingham Prognosis Index and the Adjuvant Online Decision Making Tool for Prognosis in Early-stage Breast Cancer Patients. International Journal of Preventive Medicine. ISSN 2008-7802

(2015) Specific TaqMan allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of FTO gene demonstrated that there is no association between these SNPs and risk of breast cancer in Iranian women. Advanced biomedical research. p. 136. ISSN 2277-9175 (Print) 2277-9175 (Linking)

(2015) The expression of CK-19 gene in circulating tumor cells of blood samples of metastatic breast cancer women. Research in Pharmaceutical Sciences. pp. 485-496. ISSN 1735-5362

This list was generated on Sat Nov 23 13:32:37 2024 +0330.